Share

New Study Links Combination of Hormone Therapy and Tirzepatide to Greater Weight Loss after Menopause

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, could expand treatment possibilities for millions of women struggling with obesity and obesity-related diseases after menopause. Menopause can accelerate age-related weight gain and increase the likelihood of...
Share

People with Obesity May Have a Higher Risk of Dementia

jcem_110_1cover People with obesity and high blood pressure may face a higher risk of dementia, according to a new study published in The Journal of Clinical Endocrinology & Metabolism. Dementia is a growing global public health challenge, with no cure currently available. People with dementia experience a severe decline in mental abilities, like memory, thinking and reasoning. The most common forms of dementia are Alzheimer’s disease, vascular dementia and mixed dementia. Dementia is a progressive...
Share

New Research Connections: How dkNET Allows Access to the Research Information Superhighway

dkNET Group Photo Endocrine scientists around the world can now access dkNET, a research portal established by the National Institute of Diabetes and Digestive and Kidney Diseases, which provides endocrine researchers and clinicians with cross-disciplinary access to critical new information. Endocrine News talks with emeritus Endocrine Society member and longtime researcher Robert Margolis, PhD, about how this new...
Share

COVID-19 Infection Linked to Relapse of Rare Endocrine Disorder After 19 Years

A rare case study published in JCEM Case Reports details the first known instance of a decades-dormant hormonal disorder, Cyclic Cushing Syndrome (CS), relapsing after a patient contracted COVID-19 and received standard glucocorticoid treatment. The relapse occurred after a remarkable 19-year period of remission, leading researchers to suggest that the stress of the infection and...
Share

Remembering Joel Habener, MD

Habener, Joel The world of endocrinology – and indeed the world – lost a titan at the end of 2025 in Joel Habener, MD, who passed away December 28 at the age of 88. Habener, a professor of medicine at Harvard Medical School and director of the Laboratory of Molecular Endocrinology at Massachusetts General Hospital in Boston,...
Share

Pharma Friday – January 9, 2026

An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism On January 7, Rezolute, Inc., a late-stage rare disease company focused on treating hypoglycemia caused by all forms...